glucose-na-k baxter 50 mg/ml infusionsvæske, opløsning
baxter a/s - glucosemonohydrat, kaliumchlorid, magnesiumchloridhexahydrat, natriumacetattrihydrat, natriumchlorid - infusionsvæske, opløsning - 50 mg/ml
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, type 2 - narkotika anvendt i diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trepersoners-kombinationsbehandling) som supplement til diæt og motion hos patienter, der ikke er tilstrækkeligt kontrolleret på deres maksimal tolereret dosis af metformin og et sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
kalium-natrium-glucose "braun" 1,492+2,338+55 mg/ml infusionsvæske
b. braun melsungen - glucosemonohydrat, kaliumchlorid, natriumchlorid - infusionsvæske - 1,492+2,338+55 mg/ml
kalium-natrium-glucose "fresenius kabi" infusionsvæske, opløsning
fresenius kabi ab - glucosemonohydrat, kaliumchlorid, magnesiumchloridhexahydrat, natriumacetattrihydrat, natriumchlorid - infusionsvæske, opløsning
bicavera 1,5 % glucose, 1,25 mmol/l calcium peritonealdialysevæske
fresenius medical care deutschland gmbh - calciumchloriddihydrat, glucosemonohydrat, magnesiumchloridhexahydrat, natriumchlorid, natriumhydrogencarbonat - peritonealdialysevæske
bicavera 1,5% glucose, 1,75 mmol/l calcium peritonealdialysevæske, opløsning
fresenius medical care deutschland gmbh - calciumchlorid, vandfrit, glucosemonohydrat, magnesiumchloridhexahydrat, natriumchlorid, natriumhydrogencarbonat - peritonealdialysevæske, opløsning
bicavera 2,3% glucose, 1,75 mmol/l calcium peritonealdialysevæske, opløsning
fresenius medical care deutschland gmbh - calciumchlorid, vandfrit, glucosemonohydrat, magnesiumchloridhexahydrat, natriumchlorid, natriumhydrogencarbonat - peritonealdialysevæske, opløsning
bicavera 4,25 % glucose, 1,25 mmol/l calcium peritonealdialysevæske
fresenius medical care deutschland gmbh - calciumchloridhexahydrat, glucosemonohydrat, magnesiumchloridhexahydrat, natriumchlorid, natriumhydrogencarbonat - peritonealdialysevæske
bicavera 4,25% glucose, 1,75 mmol/l calcium peritonealdialysevæske, opløsning
fresenius medical care deutschland gmbh - calciumchlorid, vandfrit, glucosemonohydrat, magnesiumchloridhexahydrat, natriumchlorid, natriumhydrogencarbonat - peritonealdialysevæske, opløsning
sitagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, type 2 - narkotika anvendt i diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. - , trepersoners-kombinationsbehandling) som supplement til diæt og motion hos patienter, der ikke er tilstrækkeligt kontrolleret på deres maksimal tolereret dosis af metformin og et sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.